Compare RPID & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RPID | OABI |
|---|---|---|
| Founded | 2006 | 2012 |
| Country | United States | United States |
| Employees | N/A | 89 |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 204.3M | 237.4M |
| IPO Year | 2021 | N/A |
| Metric | RPID | OABI |
|---|---|---|
| Price | $2.48 | $1.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $8.00 | $4.50 |
| AVG Volume (30 Days) | 171.8K | ★ 566.4K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 2.78 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $33,587,000.00 | N/A |
| Revenue This Year | $19.12 | $52.42 |
| Revenue Next Year | $18.42 | $64.69 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 19.74 | N/A |
| 52 Week Low | $2.01 | $1.22 |
| 52 Week High | $4.94 | $2.22 |
| Indicator | RPID | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 51.72 | 39.50 |
| Support Level | $2.36 | $1.32 |
| Resistance Level | $4.48 | $1.70 |
| Average True Range (ATR) | 0.14 | 0.09 |
| MACD | 0.07 | -0.00 |
| Stochastic Oscillator | 72.22 | 20.00 |
Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.
OmniAb Inc licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for its partners' drug development efforts. At the heart of the OmniAb platform is what it calls Biological Intelligence, which powers the immune systems of proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics.